Navigation Links
Centaur Animal Health Appoints New President and Chief Executive Officer.

KANSAS CITY, Kan. and PHILADELPHIA, Aug. 27, 2013 /PRNewswire/ -- Centaur Animal Health, is pleased to announce the appointment of Jeffrey Boily as President, CEO, and Director effective September 1, 2013.

Mark Metrokotsas, who has been the CEO, will become Chairman of Centaur's Board of Directors.

Boily brings over 30 years of global life sciences experience in pharmaceuticals, biotechnology, drug delivery and animal health and will be instrumental in accelerating plans toward Centaur becoming a major animal health company. Centaur has established a track record of successful execution on product initiatives and is aggressively looking to in-license additional products.

"I'm delighted to lead Centaur Animal Health as we embark on the next phase of growth," said Boily.

"Jeff's background as an entrepreneurial leader and his experience in fund-raising and partnering with large and small firms is a perfect fit for Centaur," said Mark Metrokotsas, Board Chair for Centaur Animal Health.

Jeffrey Boily is non-executive Chairman of ProteaPex Therapeutics, a firm researching and developing innovative animal health therapeutics. Most recently he was President and CEO of the Center for Animal Health Innovation which focused on identifying and funding breakthrough technologies. Previous to this, he was CEO of BioWizard, a VC funded research and information firm for biomedical scientists. He gained large company executive experience at Abbott, Rogers and Wyeth including Fort Dodge Animal Health. He holds an M.B.A. from the John Molson School of Business, Concordia U., Montreal and a B.S. in biology from the U. of Ottawa. He also serves on the Board of Directors of various healthcare companies.

About Centaur Animal Health

Centaur Animal Health is focused on developing innovative diagnostics, pharmaceuticals and nutraceuticals that address significant therapeutic needs for companion and production animals. Centaur licenses patent-protected technologies acquired from animal health or human pharmaceutical and biotechnology companies. Contract manufacturing is available in their FDA certified plant. For more information, please visit

For Media:
Jeffrey Boily
Centaur Animal Health
O: (484) 619-3685
Web Site:

SOURCE Centaur Animal Health
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
2. Henry Schein to Open NASDAQ Stock Market to Celebrate Rebranding of U.S. Animal Health Business
3. Revalesio Presents Data Showing RNS60 Alters Disease Progression in Animal Model of Alzheimers Disease Through the PI3k-Akt Pathway
4. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
5. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
6. Masimo Signs Far-Reaching Pulse Oximetry Distribution Deal with Butler Schein Animal Health
7. Small Animal Imaging (In Vivo) Market - By systems and reagents - Competitive Analysis & Global Forecasts to 2017
8. McCord Animal Health Introduces Board of Advisors
9. Peter Dinklage Joins Cruelty Free International to Call for US ban on Animal Tests for Cosmetics
10. Star Scientific and Rock Creek Pharmaceuticals Report on the Beneficial Nutritional Effects of Anatabine in an Animal Model of Ulcerative Colitis
11. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
Post Your Comments:
(Date:10/13/2015)... , Oct. 13 2015 ... addition of the "US & European ... Countries (2010-2021)" report to their offering. ... the addition of the "US & ... 16 Countries (2010-2021)" report to their ...
(Date:10/13/2015)... -- Graduate students across the country, with an interest ... have the opportunity to learn about a lesser-known ... and development process. Eli Lilly and Company (NYSE: ... from academic institutions to create an elective graduate ... Development."  Lilly will formally unveil the eLearning course ...
(Date:10/13/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... serving the pharmaceutical, biotechnology, and medical device industries, ... version of OncoWuXi, the first App in the ... and data on the go.  The OncoWuXi App ... to identify relevant tumor models for use in ...
Breaking Medicine Technology:
(Date:10/13/2015)... California (PRWEB) , ... October ... ... launched Postnatal Omega-3, a first-of-its kind product that targets the unique health ... Postnatal Omega-3” of the American Pregnancy Association ( ), utilizes Nordic ...
(Date:10/13/2015)... ... October 13, 2015 , ... T-System and Centegra Health ... 59,000 emergency department visits per year, today announced the successful and rapid deployment ... clinical, operational and financial outcomes. , In less than four days, ...
(Date:10/13/2015)... ... October 13, 2015 , ... Tempe Dental Care, a leading Tempe dentists’ office, ... IV sedation dentistry for more than 5 years. A leading cause of emergency ... painful if treatment is not timely. , Sedation dentistry provides an ...
(Date:10/13/2015)... ... 2015 , ... World Patent Marketing , a vertically integrated manufacturer and ... helps people in clearing snow away from the streets and driveways. , "The Snowplowing ... year," says Scott Cooper, CEO and Creative Director of World Patent Marketing and ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an ESPN report published ... a teammate accidentally elbowed him in the left eye during the first day of ... one of a series of setbacks, including a knee injury that has interfered with ...
Breaking Medicine News(10 mins):